The effect of NNRTIs on HIV reverse transcriptase dimerization

Current Opinion in Investigational Drugs

Volumn 4, Issue 8, 2003, Pages 966-973

  Tachedjian, Gilda ^a   Goff, Stephen P ^b  

^a BURNET INSTITUTE   (Australia)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Destabilization; Enhancement; HIV 1; NNRTIs; Protein protein interaction; RT dimerization

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 2',5' BIS O (TERT BUTYLDIMETHYLSILYL) 3' SPIRO 5' (4' AMINO 1',2' OXATHIOLE 2',2' DIOXIDE)PYRIMIDINE; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CALANOLIDE A; CALANOLIDE B; CAPRAVIRINE; DAPIVIRINE; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; ETRAVIRINE; HYDRAZONE DERIVATIVE; LOVIRIDE; N (4 TERT BUTYLBENZOYL) 2 HYDROXYNAPTHALDEHYDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; TETRAHYDROIMIDAZOBENZODIAZEPINONE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIMERIZATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBUNIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; DIMERIZATION; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0141515727     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA et al: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 337(11):725-733.
2. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ et al: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med (1999) 341(25):1865-1873.
3. Pillay D, Taylor S, Richman DD: Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol (2000) 10(4):231-253.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12(7):F51-F58.
5. Furman PA, Fyfe JA, St Clair MH, Weinhood K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H et al: Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA (1986) 83(21):8333-8337.
6. De Clercq E: The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in ther therapy of HIV-1 infection. Antiviral Res (1998) 38(3):153-179. Comprehensive review article on NNRTIs.
7. Goff SP: Retroviral reverse transcriptase: Synthesis, structure, and function. J Acquir Immune Defic Syndr (1990) 3(8): 817-831.
8. Swanstrom R, Wills J: Synthesis, assembly, and processing of viral proteins. In: Retroviruses. Coffin JM, Hughes SH, Varmus H (Eds), Cold Spring Harbor Laboratory Press, Woodbury, NY, USA (1997):263-334.
9. Telesnitsky A, Goff SP: Reverse transcriptase and generation of retroviral DNA. In: Retroviruses. Coffin JM, Hughes SH, Varmus HE (Eds), Cold Spring Harbor Laboratory Press, Woodbury, NY, USA (1997):121-160.
10. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure of 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256(5065):1783-1790.
11. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, Hzi A et al: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl Acad Sci USA (1993) 90(13):6320-6324.
12. Restle T, Muller B, Goody RS: Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J Biol Chem (1990) 265(16):8986-8988. First report suggesting that RT dimerization is a drug target.
13. Restle T, Muller B, Goody RS: RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett (1992) 300(1):97-100.
14. Tachedjian G, Aronson HE, De Los Santos M, Seehra J, McCoy JM, Goff SP: Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J Mol Biol (2003) 326(2):381-396. Study demonstrating that mutating W401 to either A or L in the p66 subunit of the RT abrogates RT dimerization and RT polymerase activity.
15. Divita G, Rittinger K, Geourjon C, Deleage G, Goody RS: Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: A two step process. J Mol Biol (1995) 245(5):508-521.
16. Sluis-Cremer N, Tachedjian G: Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem (2002) 269(21):5103-5111. Review describing small molecule inhibitors and peptides that can modulate the dimerization of HIV enzymes, protease, integrase and the reverse transcriptase.
17. Tachedjian G, Aronson HE, Goff SP: Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA (2000) 97(12):6334-6339. First demonstration of the heterodimerization of the HIV-1 reverse transcriptase in the yeast two-hybrid system.
18. Wang J, Smerdon SJ, Jager J, Kohlstaedt LA, Rice PA, Friedman JM, Steitz TA: Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci USA (1994) 91(15):7242-7246.
19. Hostomska Z, Matthews DA, Davies JF 2nd, Nodes BR, Hostomsky Z: Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem (1991) 266(22):14697-14702.
20. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, Nakashima H, Perno CF, Walker RT, Miyasaka T: Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun (1989) 165(3):1375-1381.
21. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J et al: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 343(6257):470-474.
22. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanottio B, Morelli E, Novellino E: Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives. Curr Pharm Design (2002) 8(8):615-657. Comprehensive review on first and second generation NNRTIs with details on structure activity relationships on several classes of NNRTI and their derivatives.
23. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J et al.: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (1990) 250(4986):1411-1413.
24. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schlief WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS et al.: Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA (1991) 88(15):6863-6867.
25. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M, Resnick L: U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1993) 37(5):1127-1131.
26. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme AM, Janssen CGM, Anne J et al.: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA (1993) 90(5):1711-1715.
27. Balzarini J, Perez-Perez MJ, San-Felix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ, De Clercq E: 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2′-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci USA (1992) 89(10):4392-4396.
28. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Caroll SS, Pettibone DJ: L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1995) 39(12):2602-2605.
29. Kleim JP, Bender R, Kirsch R, Meichsner C, Paessen A, Rosner M, Rubsamen-Waigmann H, Kaiser R, Wicher M, Schnewei KE, Winkler I et al.: Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1995) 399(10):2253-2257.
30. Tanaka H, Takashima H, Ubasawa M, Sekiya K, Inouye N, Baba M, Shigeta S, Walker RT, De Clercq E, Miyasaka T: Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J Med Chem (1995) 38(15):2860-2865.
31. Balzarini J, Brouwer WG, Felauer EE, De Clercq E, Karlsson A: Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res (1995) 27(3):219-236.
32. Balzarini J, Brouwer WG, Dao DC, Osika EM, De Clercq E: Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother (1996) 40(6):1454-1466.
33. Fujiwara T, Sato A, El-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen LB, Harada H, Sugimoto H et al: S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1998) 42(6):1340-1345.
34. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH II, McMahon JB, Currens MJ, Buckheit RW Jr., Hughes SH, Cragg GM, Boyd MR: The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem (1992) 35(15):2735-2743.
35. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 68(3):1660-1666.
36. Deeks SG: International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr (2001) 26(Suppl 1):25-33.
37. Molye G: The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs (2001) 61(1):19-26.
38. Condra JH, Miller MD, Hazuda DJ, Emini EA: Potential new therapies for the treatment of HIV-1 infection. Annu Rev Med (2002) 53:541-555.
39. Corbett JW, Ko SS, Rodgers JD, Jeffrey S, Bacheler LT, Klabe RM, Diamond S, Lai CM, Rabel SR, Saye JA, Adams SP et al.: Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 43(12):2893-2897.
40. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA: Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA (1994) 91(9):3911-3915.
41. Spence RA, Kati WM, Anderson KS, Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (1995) 267(5200):988-993.
42. Rittinger K, Divita G, Goody RS: Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA (1995) 92(7):8046-8049.
43. Ding J, Das K, Tantillo C, Zhang W, Clark AD Jr., Jessen S, Lu X, Hsiou Y, Jacobo-Molina A, Andries K, Pauwels R et al.: Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure (1995) 3(4):365-379.
44. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D: Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol (1995) 2(4):303-308.
45. Hsiou Y, Das K, Ding J, Clark AD Jr., Kleim JP, Rosner E: Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol (1998) 284(2):313-323.
46. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK: Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold Des (2000) 8(10):1089-1094.
47. Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, Fridborg K, Zhang H, Unge T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem (2002) 269(6):1670-1677.
48. Ren J, Esnouf RM, Hopkins AL, Warren J, Balzarini J, Stuart DI, Stammers DK: Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry (1998) 37(41):14394-14403.
49. Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, Stammers DK: Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem (2000) 275(19):14316-14320.
50. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ, Parniak MA: Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4″-amino-2″,2″-dioxo-1″,2″-oxathiole-5 ″,3′-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-rib ofuranosyl]]]-3-ethylthymine. Biochemistry (2000) 39(6):1427-1433. Study demonstrating that the uncoventional NNRTI TSAO can destabilize the RT heterodimer.
51. Sluis-Cremer N, Arion D, Parniak MA: Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol (2002) 62(2):398-405. Study of an N-acyl hydrazone inhibitor, an unconventional NNRTI, and its capacity to destabilize the RT heterodimer.
52. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, Goff SP: Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA (2001) 98(13):7188-7193. First report on the enhancement of RT dimerization by first and second generation NNRTIs in yeast and in vitro using recombinant proteins.
53. Hughes SH: Molecular matchmaking: NNRTIs can enhance the dimerization of HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA (2001) 98(13):6991-6992. Commentary on the enhancement of RT dimerization by NNRTIs and the question it raises with regard to RT and NNRTI inhibition.
54. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK, Stuart DI: Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA (1997) 94(8):3984-3989.
55. Barnard J, Borkow G, Parniak MA: The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry (1997) 36(25):7786-7792.
56. Maga G, Ubiali D, Salvetti R, Pregnolato M, Spadari S: Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob Agents Chemother (2000) 44(5):1186-1194.
57. Motakis D, Parniak MA: A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 46(6):1851-1856.
58. Balzarini J, Perez-Perez MJ, San-Felix A, Camarasa MJ, Bathurst IC, Barr PJ, De Clercq E: Kinetics of inhibitions of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide)thymine (TSAO-T). J Biol Chem (1992) 267(17):11831-11838.
59. Rodriguez-Barrios F, Perez C, Lobaton E, Velazquez S, Chamorro C, San-Felix A, Perez-Perez MJ, Camarasa MJ, Pelemans H, Balzarini J, Gago F: Identification of a putative binding site for [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide)thymine (TSAO) derivatives at the p51-p55 interface of HIV-1 reverse transcriptase. J Med Chem (2001) 44(12):1853-1865. Modeling studies demonstrating that TSAO binds differently to HIV-RT compared with conventional NNRTIs and makes significant contacts with the dimer interface.
60. Jonckheere H, Tayman JM, Balzarini J, Velazquez S, Camarasa MJ, Desmyter J, De Clercq E, Anne J: Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)] (TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunit. J Biol Chem (1994) 269(41):25255-25258.
61. Quillent C, Borman AM, Paulous S, Dauguet C, Clavel F: Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Virology (1996) 219(1):29-36.
62. Zybarth G, Carter C: Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J Virol (1995) 69(6):3878-3884.
63. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S et al.: Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA (2002) 99(22):14398-14403. Discovery of a small molecule compounds that block the interaction of Ras and Raf using a yeast two-hybrid screen in which the yeast were mutated to increase their permeability to drugs.